Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. A. Maihöfer, M. Schlepütz, J. W. Spillner, T. Schröder, R. Autschbach, S. Westphal, A. Perez-Bouza, T. Braunschweig, G. Schaelte, R. Rossaint, S. Uhlig, C. Martin, A. D. Rieg (Aachen, Bonn, Germany). Imatinib lowers the pulmonary vascular tone in human and guinea pig lung tissue. Eur Respir J 2013; 42: Suppl. 57, 489

Member's Comments

No comment yet.

Related content which might interest you: Anti-fibrotic effects of pirfenidone on pulmonary arterial vascular smooth muscle cells Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 The role of anion exchanger on pulmonary vascular response to sustained alveolar hypoxia in the isolated perfused rabbit lung Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Selective inhibition of neutrophil elastase by BAY 85-8501 improves exercise capacity and pulmonary hypertension in a porcine pancreatic elastase-induced emphysema model Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Inhaled INS1009 demonstrates localized pulmonary vasodilation activity Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Increased Cyr61 in pulmonary arterial hypertension involving in proliferation of pulmonary arterial smooth muscle cells Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Obligatory role of MEK/ERK/RSK90 in the mitogenic responses of human pulmonary artery smooth muscle cells Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Antiproliferative effects of drugs affecting different signalling pathways on rat and human pulmonary artery smooth muscle cells Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Modulation of symmetric dimethyarginine formation by apelin in human pulmonary endothelial cells Source: International Congress 2015 – Translational research in respiratory care: new findings Year: 2015 Acute hyperoxic challenge improves haemodynamics & Pulmonary vascular stiffness in interstitial lung disease-associated pulmonary hypertension Source: International Congress 2016 – Connective tissue disorders Year: 2016 Endothelial-derived MIF contributes to pulmonary endothelial cell proliferation in human pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Smooth muscle microparticles as novel biomarkers of vascular remodelling and inflammation in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Analysis of pulmonary endothelial microparticles, haemodynamics and functional class in pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Incorporation into lipid nanoparticles extends the duration of activity of treprostinil in an acute hypoxia rat model of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Erythropoietin recapitulates hemodynamic features of hypoxia-induced pulmonary hypertension in mice Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016